Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsNASALStandard

TOSYMRA

SUMATRIPTAN

Standard Dose
10MG/SPRAY
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview TOSYMRA is listed in Drugs@FDA under application 210884 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 10MG/SPRAY Sponsor TONIX MEDS Submission history Latest submission status date: 2019-01-25 00:00:00.

Structured Monograph

Clinical summary

Approval overview TOSYMRA is listed in Drugs@FDA under application 210884 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient SUMATRIPTAN Form and strength SPRAY;NASAL - 10MG/SPRAY Sponsor TONIX MEDS Submission history Latest submission status date: 2019-01-25 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.